Nestle has introduced a new protein shot that aims to aid weight management by stimulating the production of the natural GLP-1 hormone, which is similar to the effects of popular weight-loss medications.

This development coincides with the U.S. Food and Drug Administration (FDA) announcing the end of the shortage of tirzepatide, the active ingredient in Eli Lilly's weight-loss drug Zepbound, which has had an impact on the weight-loss industry.

The increased use of weight-loss drugs like Wegovy and Zepbound is leading to a rise in healthcare utilization in the United States, resulting in more patients being diagnosed and prescribed treatments for various health conditions.

This ongoing development in the field of weight-loss solutions is attracting attention from both consumers and healthcare providers.